This CDCep™ BRCA1/2 MLPA test Kit utilizes Multiplex Ligation-dependent Probe Amplification (MLPA) technology combined with capillary electrophoresis for the detection of large genomic rearrangements in BRCA1 and BRCA2 genes. It is the most widely adopted method and the established gold standard for identifying large rearrangements in these genes.
The MLPA method detects BRCA1 and BRCA2 large genomic rearrangements—including deletions and duplications—which are associated with hereditary breast and ovarian cancer.
High Sensitivity
· Precisely detects BRCA1/BRCA2 large genomic rearrangements (deletions/duplications), especially in conventional sequencing-negative cases, reducing missed diagnoses.
High-Throughput Detection
· Enables simultaneous processing of multiple samples, significantly improving efficiency for hereditary breast cancer family screening.
Low DNA Input Requirement
· Requires minimal DNA input, lowering sample demands; ideal for precious or limited specimens.
Streamlined Workflow
· Standardized protocol eliminates need for complex instrumentation or specialized training; laboratory-friendly implementation.
| Species: | Human |
| Variant Types: | Large Genomic Rearrangement(LGR) |
| Sample Type: | Blood, Tissue |
| Method: | Capillary Electrophoresis(CE) |
| Sequencing Platform: | Applied Biosystems |
| BRCA1 | BRCA2 |
Please submit a detailed description of your project. We will provide you with a customized project plan to meet your research requests. You can also send emails directly to for inquiries.
Please fill out the form below: ×
